MedTrace Logo

Medrol Dosepak Taper for Delayed Post-op Recovery After TKA

NCT05113901 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-10-23

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of a methylprednisolone taper on patients with decreased range of motion (ROM) or delayed recovery in the acute postoperative period following total knee arthroplasty (TKA).

Patients with decreased ROM or delayed recovery six weeks to three months post-TKA will improve ROM and patient-reported outcomes at two weeks post-treatment initiation of methylprednisolone taper, as compared to similar patients who receive a placebo taper.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

Methylprednisolone

21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks

DRUG

Placebo

21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2022-07-01
Completion
2022-07-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113901 on ClinicalTrials.gov